查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1421001

心血管药物市场 - 2023-2031 年全球产业分析、规模、份额、成长、趋势与预测

Cardiovascular Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 241 Pages | 商品交期: 2-10个工作天内

价格

心血管药物市场 - 报告范围

TMR 关于全球帕金森氏症治疗市场的报告研究了过去以及当前的成长趋势和机会，以获得 2023 年至 2031 年预测期内市场指标的宝贵见解。该报告提供了全球帕金森氏症治疗的收入2017- 2031年期间的市场，考虑2023年为基准年，2031年为预测年。该报告也提供了2023年至2031年全球帕金森氏症治疗市场的年复合成长率（CAGR %）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解帕金森氏症治疗市场。

市场概况
2023年市场价值 1,428 亿美元
2031 年市场价值 1956 亿美元
CAGR 3.8%

该报告深入研究了全球帕金森氏症治疗市场的竞争格局。全球帕金森氏症治疗市场的主要参与者已经确定，并对每位参与者的不同属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球帕金森氏症治疗市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概览

  • 介绍
  • 概述
  • 市场动态
  • 2017-2031年全球市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 主要产品/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：依药物类别

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依药品类别，2017-2031
    • 肾素-血管张力素系统阻断剂
      • ACE抑制剂
      • 血管张力素受体阻断剂
    • β受体阻断剂
    • 利尿剂
    • 抗凝血剂
      • 抗凝血剂
      • 血小板聚集抑制剂
    • 降血脂药
    • 其他降血压药
    • 钙通道阻断剂
    • 其他的
  • 市场吸引力分析：依药品类别

第 7 章：全球市场分析与预测：依指标分类

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依指标划分，2017-2031
    • 高血压
    • 高血脂症
    • 冠状动脉疾病
    • 週边动脉疾病
    • 心律不整
    • 其他的
  • 市场吸引力分析：依指标分类

第 8 章：全球市场分析与预测：按配销通路

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按配销通路，2017-2031
    • 医院药房
    • 零售药房
    • 网路药房
  • 市场吸引力分析：按配销通路

第 9 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2017-2031
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第 10 章：北美市场分析与预测

第 11 章：欧洲市场分析与预测

第 12 章：亚太市场分析与预测

第 13 章：拉丁美洲市场分析与预测

  • 市场价值预测：按配销通路，2017-2031
    • 医院药房
    • 零售药房
    • 网路药房
  • 市场价值预测：依国家/次区域划分，2017-2031
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 市场吸引力分析
    • 按药物类别
    • 按指示
    • 按配销通路
    • 按国家/次区域

    第 14 章：中东和非洲市场分析与预测

    第 15 章：竞争格局

    • 市场参与者 - 竞争矩阵（依公司层级和规模）
    • 市占率分析：依公司划分（2022 年）
    • 公司简介
      • AstraZeneca
      • Pfizer Inc.
      • Novartis AG
      • Merck & Co. Inc.
      • Bristol-Myers Squibb Company
      • Bayer AG
      • Sanofi
      • Boehringer Ingelheim GmbH
      • F. Hoffmann-La Roche Ltd.
      • Abbott Laboratories
      • Gilead Sciences, Inc.
      • Johnson & Johnson
      • Astellas Pharma, Inc.
      • Eli Lilly and Company
      • Otsuka Holdings Co., Ltd.
      • Takeda Pharmaceuticals Company Ltd.
    • Product Code: TMRGL33281

    Cardiovascular Drugs Market - Scope of Report

    TMR's report on the global Parkinson's disease therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Parkinson's disease therapeutics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Parkinson's disease therapeutics market from 2023 to 2031.

    The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Parkinson's disease therapeutics market.

    Market Snapshot
    Market Value in 2023US$ 142.8 Bn
    Market Value in 2031US$ 195.6 Bn
    CAGR3.8%

    Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Parkinson's disease therapeutics market.

    The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Parkinson's disease therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Parkinson's disease therapeutics market.

    The report delves into the competitive landscape of the global Parkinson's disease therapeutics market. Key players operating in the global Parkinson's disease therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Parkinson's disease therapeutics market profiled in this report.

    Key Questions Answered in Global Parkinson's disease therapeutics Market Report:

    • What is the sales/revenue generated by Parkinson's disease therapeutics across all regions during the forecast period?
    • What are the opportunities in the global Parkinson's disease therapeutics market?
    • What are the major drivers, restraints, opportunities, and threats in the market?
    • Which regional market is set to expand at the fastest CAGR during the forecast period?
    • Which segment is expected to generate the highest revenue globally in 2031?
    • Which segment is projected to expand at the highest CAGR during the forecast period?
    • What are the market positions of different companies operating in the global market?

    Cardiovascular Drugs Market - Research Objectives and Research Approach

    The comprehensive report on the global Parkinson's disease therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

    For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

    The report analyzes the global Parkinson's disease therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Parkinson's disease therapeutics market.

    Table of Contents

    1. Preface

    • 1.1. Market Definition and Scope
    • 1.2. Market Segmentation
    • 1.3. Key Research Objectives
    • 1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Cardiovascular Drugs Market

    4. Market Overview

    • 4.1. Introduction
      • 4.1.1. Product Definition
      • 4.1.2. Industry Evolution/Developments
    • 4.2. Overview
    • 4.3. Market Dynamics
      • 4.3.1. Drivers
      • 4.3.2. Restraints
      • 4.3.3. Opportunities
    • 4.4. Global Cardiovascular Drugs Market Analysis and Forecast, 2017-2031

    5. Key Insights

    • 5.1. Pipeline Analysis
    • 5.2. Key Product/Brand Analysis
    • 5.3. Key Mergers & Acquisitions
    • 5.4. COVID-19 Pandemic Impact on Industry

    6. Global Cardiovascular Drugs Market Analysis and Forecast, by Drug Class

    • 6.1. Introduction & Definition
    • 6.2. Key Findings/Developments
    • 6.3. Market Value Forecast, by Drug Class, 2017-2031
      • 6.3.1. Renin-Angiotensin System Blockers
        • 6.3.1.1. ACE Inhibitors
        • 6.3.1.2. Angiotensin Receptor Blockers
      • 6.3.2. Beta Blockers
      • 6.3.3. Diuretics
      • 6.3.4. Anti-Clotting Agents
        • 6.3.4.1. Anti-Coagulants
        • 6.3.4.2. Platelet Aggregation Inhibitors
      • 6.3.5. Antihyperlipidemics
      • 6.3.6. Other Antihypertensive
      • 6.3.7. Calcium Channel Blockers
      • 6.3.8. Others
    • 6.4. Market Attractiveness Analysis, by Drug Class

    7. Global Cardiovascular Drugs Market Analysis and Forecast, by Indication

    • 7.1. Introduction & Definition
    • 7.2. Key Findings/Developments
    • 7.3. Market Value Forecast, by Indication, 2017-2031
      • 7.3.1. Hypertension
      • 7.3.2. Hyperlipidemia
      • 7.3.3. Coronary Artery Disease
      • 7.3.4. Peripheral Artery Disease
      • 7.3.5. Arrhythmia
      • 7.3.6. Others
    • 7.4. Market Attractiveness Analysis, by Indication

    8. Global Cardiovascular Drugs Market Analysis and Forecast, by Distribution Channel

    • 8.1. Introduction & Definition
    • 8.2. Key Findings/Developments
    • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
      • 8.3.1. Hospital Pharmacy
      • 8.3.2. Retail Pharmacy
      • 8.3.3. Online Pharmacy
    • 8.4. Market Attractiveness Analysis, by Distribution Channel

    9. Global Cardiovascular Drugs Market Analysis and Forecast, by Region

    • 9.1. Key Findings
    • 9.2. Market Value Forecast, by Region, 2017-2031
      • 9.2.1. North America
      • 9.2.2. Europe
      • 9.2.3. Asia Pacific
      • 9.2.4. Latin America
      • 9.2.5. Middle East & Africa
    • 9.3. Market Attractiveness Analysis, by Region

    10. North America Cardiovascular Drugs Market Analysis and Forecast

    • 10.1. Introduction
    • 10.2. Key Findings
    • 10.3. Market Value Forecast, by Drug Class, 2017-2031
      • 10.3.1. Renin-Angiotensin System Blockers
        • 10.3.1.1. ACE Inhibitors
        • 10.3.1.2. Angiotensin Receptor Blockers
      • 10.3.2. Beta Blockers
      • 10.3.3. Diuretics
      • 10.3.4. Anti-Clotting Agents
        • 10.3.4.1. Anti-Coagulants
        • 10.3.4.2. Platelet Aggregation Inhibitors
      • 10.3.5. Antihyperlipidemics
      • 10.3.6. Other Antihypertensive
      • 10.3.7. Calcium Channel Blockers
      • 10.3.8. Others
    • 10.4. Market Value Forecast, by Indication, 2017-2031
      • 10.4.1. Hypertension
      • 10.4.2. Hyperlipidemia
      • 10.4.3. Coronary Artery Disease
      • 10.4.4. Peripheral Artery Disease
      • 10.4.5. Arrhythmia
      • 10.4.6. Others
    • 10.5. Market Value Forecast, by Distribution Channel, 2017-2031
      • 10.5.1. Hospital Pharmacy
      • 10.5.2. Retail Pharmacy
      • 10.5.3. Online Pharmacy
    • 10.6. Market Value Forecast, by Country, 2017-2031
      • 10.6.1. U.S.
      • 10.6.2. Canada
    • 10.7. Market Attractiveness Analysis
      • 10.7.1. By Drug Class
      • 10.7.2. By Indication
      • 10.7.3. By Distribution Channel
      • 10.7.4. By Country

    11. Europe Cardiovascular Drugs Market Analysis and Forecast

    • 11.1. Introduction
    • 11.2. Key Findings
    • 11.3. Market Value Forecast, by Drug Class, 2017-2031
      • 11.3.1. Renin-Angiotensin System Blockers
        • 11.3.1.1. ACE Inhibitors
        • 11.3.1.2. Angiotensin Receptor Blockers
      • 11.3.2. Beta Blockers
      • 11.3.3. Diuretics
      • 11.3.4. Anti-Clotting Agents
        • 11.3.4.1. Anti-Coagulants
        • 11.3.4.2. Platelet Aggregation Inhibitors
      • 11.3.5. Antihyperlipidemics
      • 11.3.6. Other Antihypertensive
      • 11.3.7. Calcium Channel Blockers
      • 11.3.8. Others
    • 11.4. Market Value Forecast, by Indication, 2017-2031
      • 11.4.1. Hypertension
      • 11.4.2. Hyperlipidemia
      • 11.4.3. Coronary Artery Disease
      • 11.4.4. Peripheral Artery Disease
      • 11.4.5. Arrhythmia
      • 11.4.6. Others
    • 11.5. Market Value Forecast, by Distribution Channel, 2017-2031
      • 11.5.1. Hospital Pharmacy
      • 11.5.2. Retail Pharmacy
      • 11.5.3. Online Pharmacy
    • 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
      • 11.6.1. Germany
      • 11.6.2. U.K.
      • 11.6.3. France
      • 11.6.4. Italy
      • 11.6.5. Spain
      • 11.6.6. Rest of Europe
    • 11.7. Market Attractiveness Analysis
      • 11.7.1. By Drug Class
      • 11.7.2. By Indication
      • 11.7.3. By Distribution Channel
      • 11.7.4. By Country/Sub-region

    12. Asia Pacific Cardiovascular Drugs Market Analysis and Forecast

    • 12.1. Introduction
    • 12.2. Key Findings
    • 12.3. Market Value Forecast, by Drug Class, 2017-2031
      • 12.3.1. Renin-Angiotensin System Blockers
        • 12.3.1.1. ACE Inhibitors
        • 12.3.1.2. Angiotensin Receptor Blockers
      • 12.3.2. Beta Blockers
      • 12.3.3. Diuretics
      • 12.3.4. Anti-Clotting Agents
        • 12.3.4.1. Anti-Coagulants
        • 12.3.4.2. Platelet Aggregation Inhibitors
      • 12.3.5. Antihyperlipidemics
      • 12.3.6. Other Antihypertensive
      • 12.3.7. Calcium Channel Blockers
      • 12.3.8. Others
    • 12.4. Market Value Forecast, by Indication, 2017-2031
      • 12.4.1. Hypertension
      • 12.4.2. Hyperlipidemia
      • 12.4.3. Coronary Artery Disease
      • 12.4.4. Peripheral Artery Disease
      • 12.4.5. Arrhythmia
      • 12.4.6. Others
    • 12.5. Market Value Forecast, by Distribution Channel, 2017-2031
      • 12.5.1. Hospital Pharmacy
      • 12.5.2. Retail Pharmacy
      • 12.5.3. Online Pharmacy
    • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
      • 12.6.1. China
      • 12.6.2. Japan
      • 12.6.3. India
      • 12.6.4. Australia & New Zealand
      • 12.6.5. Rest of Asia Pacific
    • 12.7. Market Attractiveness Analysis
      • 12.7.1. By Drug Class
      • 12.7.2. By Indication
      • 12.7.3. By Distribution Channel
      • 12.7.4. By Country/Sub-region

    13. Latin America Cardiovascular Drugs Market Analysis and Forecast

    • 13.1. Introduction
    • 13.2. Key Findings
    • 13.3. Market Value Forecast, by Drug Class, 2017-2031
      • 13.3.1. Renin-Angiotensin System Blockers
        • 13.3.1.1. ACE Inhibitors
        • 13.3.1.2. Angiotensin Receptor Blockers
      • 13.3.2. Beta Blockers
      • 13.3.3. Diuretics
      • 13.3.4. Anti-Clotting Agents
        • 13.3.4.1. Anti-Coagulants
        • 13.3.4.2. Platelet Aggregation Inhibitors
      • 13.3.5. Antihyperlipidemics
      • 13.3.6. Other Antihypertensive
      • 13.3.7. Calcium Channel Blockers
      • 13.3.8. Others
    • 13.4. Market Value Forecast, by Indication, 2017-2031
        • 13.4.1.1. Hypertension
        • 13.4.1.2. Hyperlipidemia
        • 13.4.1.3. Coronary Artery Disease
        • 13.4.1.4. Peripheral Artery Disease
        • 13.4.1.5. Arrhythmia
        • 13.4.1.6. Others
    • 13.5. Market Value Forecast, by Distribution Channel, 2017-2031
      • 13.5.1. Hospital Pharmacy
      • 13.5.2. Retail Pharmacy
      • 13.5.3. Online Pharmacy
    • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
      • 13.6.1. Brazil
      • 13.6.2. Mexico
      • 13.6.3. Rest of Latin America
    • 13.7. Market Attractiveness Analysis
      • 13.7.1. By Drug Class
      • 13.7.2. By Indication
      • 13.7.3. By Distribution Channel
      • 13.7.4. By Country/Sub-region

    14. Middle East & Africa Cardiovascular Drugs Market Analysis and Forecast

    • 14.1. Introduction
    • 14.2. Key Findings
    • 14.3. Market Value Forecast, by Drug Class, 2017-2031
      • 14.3.1. Renin-Angiotensin System Blockers
        • 14.3.1.1. ACE Inhibitors
        • 14.3.1.2. Angiotensin Receptor Blockers
      • 14.3.2. Beta Blockers
      • 14.3.3. Diuretics
      • 14.3.4. Anti-Clotting Agents
        • 14.3.4.1. Anti-Coagulants
        • 14.3.4.2. Platelet Aggregation Inhibitors
      • 14.3.5. Antihyperlipidemics
      • 14.3.6. Other Antihypertensive
      • 14.3.7. Calcium Channel Blockers
      • 14.3.8. Others
    • 14.4. Market Value Forecast, by Indication, 2017-2031
      • 14.4.1. Hypertension
      • 14.4.2. Hyperlipidemia
      • 14.4.3. Coronary Artery Disease
      • 14.4.4. Peripheral Artery Disease
      • 14.4.5. Arrhythmia
      • 14.4.6. Others
    • 14.5. Market Value Forecast, by Distribution Channel, 2017-2031
      • 14.5.1. Hospital Pharmacy
      • 14.5.2. Retail Pharmacy
      • 14.5.3. Online Pharmacy
    • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
      • 14.6.1. GCC Countries
      • 14.6.2. South Africa
      • 14.6.3. Rest of Middle East & Africa
    • 14.7. Market Attractiveness Analysis
      • 14.7.1. By Drug Class
      • 14.7.2. By Indication
      • 14.7.3. By Distribution Channel
      • 14.7.4. By Country/Sub-region

    15. Competition Landscape

    • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
    • 15.2. Market Share Analysis, by Company (2022)
    • 15.3. Company Profiles
      • 15.3.1. AstraZeneca
        • 15.3.1.1. Company Overview
        • 15.3.1.2. Product Portfolio
        • 15.3.1.3. SWOT Analysis
        • 15.3.1.4. Financial Overview
        • 15.3.1.5. Strategic Overview
      • 15.3.2. Pfizer Inc.
        • 15.3.2.1. Company Overview
        • 15.3.2.2. Product Portfolio
        • 15.3.2.3. SWOT Analysis
        • 15.3.2.4. Financial Overview
        • 15.3.2.5. Strategic Overview
      • 15.3.3. Novartis AG
        • 15.3.3.1. Company Overview
        • 15.3.3.2. Product Portfolio
        • 15.3.3.3. SWOT Analysis
        • 15.3.3.4. Financial Overview
        • 15.3.3.5. Strategic Overview
      • 15.3.4. Merck & Co. Inc.
        • 15.3.4.1. Company Overview
        • 15.3.4.2. Product Portfolio
        • 15.3.4.3. SWOT Analysis
        • 15.3.4.4. Financial Overview
        • 15.3.4.5. Strategic Overview
      • 15.3.5. Bristol-Myers Squibb Company
        • 15.3.5.1. Company Overview
        • 15.3.5.2. Product Portfolio
        • 15.3.5.3. SWOT Analysis
        • 15.3.5.4. Financial Overview
        • 15.3.5.5. Strategic Overview
      • 15.3.6. Bayer AG
        • 15.3.6.1. Company Overview
        • 15.3.6.2. Product Portfolio
        • 15.3.6.3. SWOT Analysis
        • 15.3.6.4. Financial Overview
        • 15.3.6.5. Strategic Overview
      • 15.3.7. Sanofi
        • 15.3.7.1. Company Overview
        • 15.3.7.2. Product Portfolio
        • 15.3.7.3. SWOT Analysis
        • 15.3.7.4. Financial Overview
        • 15.3.7.5. Strategic Overview
      • 15.3.8. Boehringer Ingelheim GmbH
        • 15.3.8.1. Company Overview
        • 15.3.8.2. Product Portfolio
        • 15.3.8.3. SWOT Analysis
        • 15.3.8.4. Financial Overview
        • 15.3.8.5. Strategic Overview
      • 15.3.9. F. Hoffmann-La Roche Ltd.
        • 15.3.9.1. Company Overview
        • 15.3.9.2. Product Portfolio
        • 15.3.9.3. SWOT Analysis
        • 15.3.9.4. Financial Overview
        • 15.3.9.5. Strategic Overview
      • 15.3.10. Abbott Laboratories
        • 15.3.10.1. Company Overview
        • 15.3.10.2. Product Portfolio
        • 15.3.10.3. SWOT Analysis
        • 15.3.10.4. Financial Overview
        • 15.3.10.5. Strategic Overview
      • 15.3.11. Gilead Sciences, Inc.
        • 15.3.11.1. Company Overview
        • 15.3.11.2. Product Portfolio
        • 15.3.11.3. SWOT Analysis
        • 15.3.11.4. Financial Overview
        • 15.3.11.5. Strategic Overview
      • 15.3.12. Johnson & Johnson
        • 15.3.12.1. Company Overview
        • 15.3.12.2. Product Portfolio
        • 15.3.12.3. SWOT Analysis
        • 15.3.12.4. Financial Overview
        • 15.3.12.5. Strategic Overview
      • 15.3.13. Astellas Pharma, Inc.
        • 15.3.13.1. Company Overview
        • 15.3.13.2. Product Portfolio
        • 15.3.13.3. SWOT Analysis
        • 15.3.13.4. Financial Overview
        • 15.3.13.5. Strategic Overview
      • 15.3.14. Eli Lilly and Company
        • 15.3.14.1. Company Overview
        • 15.3.14.2. Product Portfolio
        • 15.3.14.3. SWOT Analysis
        • 15.3.14.4. Financial Overview
        • 15.3.14.5. Strategic Overview
      • 15.3.15. Otsuka Holdings Co., Ltd.
        • 15.3.15.1. Company Overview
        • 15.3.15.2. Product Portfolio
        • 15.3.15.3. SWOT Analysis
        • 15.3.15.4. Financial Overview
        • 15.3.15.5. Strategic Overview
      • 15.3.16. Takeda Pharmaceuticals Company Ltd.
        • 15.3.16.1. Company Overview
        • 15.3.16.2. Product Portfolio
        • 15.3.16.3. SWOT Analysis
        • 15.3.16.4. Financial Overview
        • 15.3.16.5. Strategic Overview

    List of Tables

    • Table 01: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
    • Table 02: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
    • Table 03: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
    • Table 04: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Region, 2017-2031
    • Table 05: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017-2031
    • Table 06: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
    • Table 07: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
    • Table 08: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
    • Table 09: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
    • Table 10: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
    • Table 11: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
    • Table 12: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
    • Table 13: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
    • Table 14: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
    • Table 15: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
    • Table 16: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
    • Table 17: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
    • Table 18: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
    • Table 19: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
    • Table 20: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
    • Table 21: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
    • Table 22: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
    • Table 23: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
    • Table 24: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    List of Figures

    • Figure 01: Global Cardiovascular Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
    • Figure 02: Global Cardiovascular Drugs Market Revenue (US$ Mn), by Drug Class, 2022
    • Figure 03: Global Cardiovascular Drugs Market Value Share, by Drug Class, 2022
    • Figure 04: Global Cardiovascular Drugs Market Revenue (US$ Mn), by Indication, 2022
    • Figure 05: Global Cardiovascular Drugs Market Value Share, by Indication, 2022
    • Figure 06: Global Cardiovascular Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022
    • Figure 07: Global Cardiovascular Drugs Market Value Share, by Distribution Channel, 2022
    • Figure 08: Global Cardiovascular Drugs Market Value Share, by Region, 2022
    • Figure 09: Global Cardiovascular Drugs Market Value (US$ Mn) Forecast, 2023-2031
    • Figure 10: Global Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
    • Figure 11: Global Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
    • Figure 12: Global Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
    • Figure 13: Global Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023-2031
    • Figure 14: Global Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
    • Figure 15: Global Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
    • Figure 16: Global Cardiovascular Drugs Market Value Share Analysis, by Region, 2022 and 2031
    • Figure 17: Global Cardiovascular Drugs Market Attractiveness Analysis, by Region, 2022-2031
    • Figure 18: North America Cardiovascular Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
    • Figure 19: North America Cardiovascular Drugs Market Attractiveness Analysis, by Country, 2023-2031
    • Figure 20: North America Cardiovascular Drugs Market Value Share Analysis, by Country, 2022 and 2031
    • Figure 21: North America Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
    • Figure 22: North America Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
    • Figure 23: North America Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
    • Figure 24: North America Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
    • Figure 25: North America Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023-2031
    • Figure 26: North America Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
    • Figure 27: Europe Cardiovascular Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
    • Figure 28: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
    • Figure 29: Europe Cardiovascular Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
    • Figure 30: Europe Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
    • Figure 31: Europe Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
    • Figure 32: Europe Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
    • Figure 33: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
    • Figure 34: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023-2031
    • Figure 35: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
    • Figure 36: Asia Pacific Cardiovascular Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
    • Figure 37: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
    • Figure 38: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
    • Figure 39: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
    • Figure 40: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
    • Figure 41: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
    • Figure 42: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
    • Figure 43: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023-2031
    • Figure 44: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
    • Figure 45: Latin America Cardiovascular Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
    • Figure 46: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
    • Figure 47: Latin America Cardiovascular Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
    • Figure 48: Latin America Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
    • Figure 49: Latin America Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
    • Figure 50: Latin America Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
    • Figure 51: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
    • Figure 52: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023-2031
    • Figure 53: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
    • Figure 54: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
    • Figure 55: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
    • Figure 56: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
    • Figure 57: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
    • Figure 58: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
    • Figure 59: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
    • Figure 60: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
    • Figure 61: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023-2031
    • Figure 62: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031